After CRT, 22 (15.3%) patients with tumor PD-L1 ≥ 1% as assessed per VENTANA PD-L1 (SP263) Assay (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Basel, Switzerland), received consolidation durvalumab 10 mg/kg every two weeks for up to 24 cycles (median 14, minimum 2). This evidence concerns the gene CD274 and neoplasm.